{Reference Type}: Journal Article
{Title}: A nomogram to predict intracranial hypertension in moderate traumatic brain injury patients.
{Author}: Li Z;Xu F;Zhang T;Zhao B;Cai Y;Yang H;Li D;Chen M;Zhao T;Zhang X;Zhao L;Ge S;Qu Y;
{Journal}: World Neurosurg
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 10
{Factor}: 2.21
{DOI}: 10.1016/j.wneu.2024.04.006
{Abstract}: <B>OBJECTIVE: </B>Patients with moderate traumatic brain injury (TBI) are under the threat of intracranial hypertension (IHT). However, it is unclear which moderate TBI patient will develop IHT and should receive intracranial pressure (ICP)-lowering treatment or invasive ICP monitoring after admission. The purpose of the present study was to develop and validate a prediction model that estimates the risk of IHT in moderate TBI patients.<BR><B>METHODS: </B>Baseline data collected on admission of 296 moderate TBI patients with Glasgow Coma Scale (GCS) score of 9-11 was collected and analyzed. Multi-variable logistic regression modeling with backward stepwise elimination was used to develop a prediction model for IHT. The discrimination efficacy, calibration efficacy, and clinical utility of the prediction model were evaluated. Finally, the prediction model was validated in a separate cohort of 122 patients from 3 hospitals.<BR><B>RESULTS: </B>Four independent prognostic factors for IHT were identified: GCS score, Marshall head computed tomography score, injury severity score and location of contusion. The C-statistic of the prediction model in internal validation was 84.30% (95% confidence interval [CI]: 0.794-0.892). The area under the curve for the prediction model in external validation was 82.80% (95% CI: 0.747∼0.909).<BR><B>CONCLUSIONS: </B>A prediction model based on baseline parameters was found to be highly sensitive in distinguishing moderate TBI patients with GCS score of 9-11 who would suffer IHT. The high discriminative ability of the prediction model supports its use in identifying moderate TBI patients with GCS score of 9-11 who need ICP-lowering therapy or invasive ICP monitoring.